CN104519902B - 双酰化glp‑1衍生物 - Google Patents

双酰化glp‑1衍生物 Download PDF

Info

Publication number
CN104519902B
CN104519902B CN201380024302.6A CN201380024302A CN104519902B CN 104519902 B CN104519902 B CN 104519902B CN 201380024302 A CN201380024302 A CN 201380024302A CN 104519902 B CN104519902 B CN 104519902B
Authority
CN
China
Prior art keywords
amino
carboxyls
caproyl
bytyry
glp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380024302.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104519902A (zh
Inventor
J．科福伊德
P.加里巴
J.劳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN104519902A publication Critical patent/CN104519902A/zh
Application granted granted Critical
Publication of CN104519902B publication Critical patent/CN104519902B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380024302.6A 2012-05-08 2013-05-02 双酰化glp‑1衍生物 Active CN104519902B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP12167091 2012-05-08
EP12167091.3 2012-05-08
US201261646470P 2012-05-14 2012-05-14
US61/646470 2012-05-14
US201261741770P 2012-09-06 2012-09-06
EP12183246 2012-09-06
US61/741770 2012-09-06
EP12183246.3 2012-09-06
PCT/EP2013/059112 WO2013167454A1 (en) 2012-05-08 2013-05-02 Double-acylated glp-1 derivatives

Publications (2)

Publication Number Publication Date
CN104519902A CN104519902A (zh) 2015-04-15
CN104519902B true CN104519902B (zh) 2017-10-27

Family

ID=49550172

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380024302.6A Active CN104519902B (zh) 2012-05-08 2013-05-02 双酰化glp‑1衍生物

Country Status (5)

Country Link
US (3) US10000542B2 (enExample)
EP (1) EP2846823B1 (enExample)
JP (1) JP6250034B2 (enExample)
CN (1) CN104519902B (enExample)
WO (1) WO2013167454A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107266558A (zh) 2011-09-06 2017-10-20 诺沃—诺迪斯克有限公司 Glp‑1衍生物
EP2846823B1 (en) 2012-05-08 2019-12-04 Novo Nordisk A/S Double-acylated glp-1 derivatives
CN104411322B (zh) * 2012-05-08 2017-05-24 诺和诺德股份有限公司 双酰化glp‑1衍生物
AR096440A1 (es) 2013-05-28 2015-12-30 Takeda Pharmaceuticals Co Compuesto peptídico agonista del receptor del péptido similar al glucagón tipo i (glp-1) y del péptido insulinotrópico dependiente de glucosa (gip)
WO2014202727A1 (en) 2013-06-20 2014-12-24 Novo Nordisk A/S Glp-1 derivatives and uses thereof
EP3033112B1 (en) * 2013-08-15 2020-10-07 Novo Nordisk A/S Glp-1 derivatives, and uses thereof
CA2939763A1 (en) * 2014-02-18 2015-08-27 Novo Nordisk A/S Stable glucagon analogues and use for treatment of hypoglycaemia
ES2741507T3 (es) * 2014-04-07 2020-02-11 Novo Nordisk As Compuestos de glp-1 acilados doblemente
JP2018012644A (ja) * 2014-11-26 2018-01-25 武田薬品工業株式会社 ペプチド化合物
EP3226906B1 (en) 2014-11-27 2019-06-12 Novo Nordisk A/S Glp-1 derivatives and uses thereof
JP6691125B2 (ja) 2014-12-17 2020-04-28 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体及びその使用
EP3467106B1 (en) 2016-05-24 2025-07-09 Takeda Pharmaceutical Company Limited Peptide compound
TW201821434A (zh) * 2016-10-10 2018-06-16 法商賽諾菲公司 製備包含親脂性修飾的離胺酸側鏈的肽的方法
CN109248323B (zh) * 2017-07-14 2023-09-08 杭州先为达生物科技有限公司 酰化的glp-1衍生物
HUE066356T2 (hu) 2017-08-24 2024-07-28 Novo Nordisk As GLP-1 készítmények és alkalmazásaik
IL322969A (en) * 2017-10-12 2025-10-01 Novo Nordisk As Semaglutide in medical therapy
UA128210C2 (uk) 2018-04-05 2024-05-08 Сан Фармасьютікал Індастріз Лімітед Аналог glp-1
WO2019200594A1 (zh) 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 酰化的glp-1衍生物
CN116925237A (zh) 2019-12-31 2023-10-24 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
PE20221575A1 (es) 2020-02-18 2022-10-06 Novo Nordisk As Formulaciones farmaceuticas
EP4222176A4 (en) 2020-09-30 2024-02-28 Beijing QL Biopharmaceutical Co., Ltd. POLYPEPTIDE CONJUGATES AND METHODS OF USE
CN113461519A (zh) * 2021-08-12 2021-10-01 浙江泽瑞生物医药有限公司 一种十八烷二酸单叔丁酯-pfp的制备方法
KR20240163717A (ko) 2022-03-30 2024-11-19 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 폴리펩티드 접합체의 액체 약학 조성물 및 그의 사용 방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5336782A (en) 1991-04-24 1994-08-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester
JP3149958B2 (ja) * 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
WO1999043706A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Derivatives of glp-1 analogs
US6589503B1 (en) * 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
AU5027299A (en) 1998-07-31 2000-02-28 Novo Nordisk A/S Use of glp-1 and analogues for preventing type ii diabetes
US20040121941A1 (en) 1999-09-28 2004-06-24 Burm Brigitte Elisa Anna Novel inhibitors of prenylated pyrophosphate consuming enzymes
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
JP2007537141A (ja) 2003-12-18 2007-12-20 ノボ　ノルディスク　アクティーゼルスカブ 新規なｇｌｐ−１化合物
ES2438145T3 (es) 2005-02-02 2014-01-16 Novo Nordisk A/S Nuevos derivados de insulina
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
US20110144010A1 (en) 2007-06-01 2011-06-16 Novo Nordisk A/S Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
ES2672770T3 (es) 2007-09-05 2018-06-18 Novo Nordisk A/S Derivados del péptido-1 similar al glucagón y su uso farmacéutico
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
CA2784757A1 (en) 2009-12-16 2011-07-07 Novo Nordisk A/S Double-acylated glp-1 derivatives
US9708383B2 (en) * 2010-11-09 2017-07-18 Novo Nordisk A/S Double-acylated GLP-1 derivatives
CN107266558A (zh) 2011-09-06 2017-10-20 诺沃—诺迪斯克有限公司 Glp‑1衍生物
EP2846823B1 (en) 2012-05-08 2019-12-04 Novo Nordisk A/S Double-acylated glp-1 derivatives
CN104411322B (zh) * 2012-05-08 2017-05-24 诺和诺德股份有限公司 双酰化glp‑1衍生物

Also Published As

Publication number Publication date
CN104519902A (zh) 2015-04-15
US10604554B2 (en) 2020-03-31
US20200123215A1 (en) 2020-04-23
EP2846823B1 (en) 2019-12-04
EP2846823A1 (en) 2015-03-18
JP2015517477A (ja) 2015-06-22
JP6250034B2 (ja) 2017-12-20
US10000542B2 (en) 2018-06-19
WO2013167454A1 (en) 2013-11-14
US20180244742A1 (en) 2018-08-30
US20150133374A1 (en) 2015-05-14
US11518795B2 (en) 2022-12-06

Similar Documents

Publication Publication Date Title
US11518795B2 (en) Double-acylated GLP-1 derivatives
CN103200966B (zh) 具有接头的双-酰化的glp-1衍生物
CN105377306B (zh) Glp-1衍生物和其用途
EP3226906B1 (en) Glp-1 derivatives and uses thereof
CN104411322B (zh) 双酰化glp‑1衍生物
CN106117344B (zh) 双酰化glp-1衍生物
CN102791731B (zh) Glp-1类似物和衍生物
CN107266558A (zh) Glp‑1衍生物
CN107108714A (zh) Glp‑1衍生物及其用途
CN105451776A (zh) Glp-1衍生物及其用途
CN104185639B (zh) Glp-1前体药物
ES2770599T3 (es) Derivados de GLP-1 doble-acilados

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Denmark bagsvaerd

Applicant after: Novo Nordisk limited company

Address before: Denmark bagsvaerd

Applicant before: NOVO NORDISK AS

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: NOVO NORDISK A/S (A/S) TO: NOVO NORDISK A/S

Free format text: CORRECT: ADDRESS; FROM:

GR01 Patent grant
GR01 Patent grant